Video Experimental Relacionado
Updated: May 11, 2026
09:05
Meal Duration as a Measure of Orofacial Nociceptive Responses in Rodents
Published on: January 10, 2014
7.7K
Toxina botulínica-A, generando una hipótesis para la terapia del dolor orofacial
Yair Sharav1, Rafael Benoliel2, Yaron Haviv1
1Department of Oral Medicine, Sedation and Imaging, Hadassah Medical Center, Faculty of Dental Medicine, Hebrew University of Jerusalem, Jerusalem 91120, Israel.
Toxins
|August 27, 2025
Resumen
La toxina botulínica tipo A (BoNT-A) ofrece un tratamiento seguro y sostenido para diversas afecciones de dolor orofacial, incluidos los tipos neuropáticos, miofasciales y neurovasculares. Esto ofrece una alternativa a los medicamentos diarios para el control del dolor crónico.
Área de la Ciencia:
- Neurología
- Medicina para el dolor
- Farmacología
Sus antecedentes:
- El dolor orofacial presenta diversas afecciones, incluidos trastornos musculoesqueléticos, neuropáticos y neurovasculares.
- La farmacoterapia profiláctica convencional a menudo no logra tratar a un subconjunto significativo de pacientes con dolor orofacial refractario.
Objetivo del estudio:
- Explorar las propiedades analgésicas y los mecanismos neuromoduladores de la toxina botulínica tipo A (BoNT-A) para el dolor orofacial.
- Proponer una hipótesis para la acción terapéutica segmental de BoNT-A en varios trastornos del dolor orofacial.
- Discutir las ventajas de BoNT-A para la profilaxis del dolor crónico en comparación con los medicamentos diarios.
Principales métodos:
- Revisión de la literatura existente sobre la toxina botulínica tipo A (BoNT-A) en el tratamiento del dolor orofacial.
- Análisis de la eficacia de BoNT-A en condiciones de dolor neuropático, miofascial y neurovascular orofacial.
- Exploración de los mecanismos neuromoduladores que subyacen a los efectos terapéuticos de BoNT-A.
Principales resultados:
- La toxina botulínica tipo A (BoNT-A) demuestra una eficacia creciente en un espectro de trastornos del dolor orofacial.
- BoNT-A proporciona un efecto analgésico seguro y sostenido después de una sola aplicación, en contraste con la farmacoterapia diaria.
- El estudio describe el potencial de BoNT-A en el manejo del dolor orofacial crónico refractario a los tratamientos convencionales.
Conclusiones:
- La toxina botulínica tipo A (BoNT-A) es un agente terapéutico prometedor para diversas afecciones de dolor orofacial.
- La comprensión de las acciones neuromoduladoras de BoNT-A apoya su aplicación en el tratamiento del dolor orofacial crónico.
- BoNT-A ofrece una alternativa segura y efectiva para pacientes con dolor orofacial refractario, reduciendo la necesidad de medicación diaria.
Videos de Conceptos Relacionados
01:44Nociception
Nociception—the ability to feel pain—is essential for an organism’s survival and overall well-being. Noxious stimuli such as piercing pain from a sharp object, heat from an open flame, or contact with corrosive chemicals are first detected by sensory receptors, called nociceptors, located on nerve endings. Nociceptors express ion channels that convert noxious stimuli into electrical signals. When these signals reach the brain via sensory neurons, they are perceived as pain. Thus, pain helps the...
01:26Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
The binding of dantrolene to the RYR1...
01:31Skeletal Muscle Relaxants: Therapeutic Uses
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx as...
01:25Analgesia and Pain Management
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
01:15Opioid Analgesics: Synthetic and Semisynthetic Opioids
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
01:26Pharmaceutical Poisoning: Treatment Strategies
Treatment strategies for poisoning are a critical aspect of emergency medicine, focusing on preventing the absorption of toxins and enhancing their elimination. When a poisoning incident occurs, the first response is to halt exposure and decontaminate the patient, particularly through gastrointestinal (GI) methods if the poison was ingested.Gastrointestinal Decontamination Techniques:Activated charcoal is the cornerstone of GI decontamination. It works through adsorption, binding the toxin to...